N@N

ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB: INSV) today announced the completion of final oral arguments to a three-judge panel of the United States Patent and Trademark Office (USPTO) related to patent interference litigation with the University of California, San Francisco. The Company continues to believe that the Universityas case is without merit. The panel of judges will make their decision based on the oral arguments and previously filed written evidence in this case. The Company awaits a decision in this case.

In 2009, the Regents of the University of California asserted that the inventions contained in certain U.S. patents covering AzaSite were made by a former employee of the University alone and without collaboration with InSite Vision. The University is asserting that it is entitled to an award of the inventions.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The companyas product portfolio utilizes InSite Visionas proven DuraSite bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Visionas clinical-stage ophthalmic product pipeline includes AzaSite Plus^a" (ISV-502) and DexaSite^a" (ISV-305) for the treatment of eye infections, BromSite^a" (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit [ www.insitevision.com ].

Forward-looking Statements

This news release contains certain statements of a forward looking nature relating to future events, including the expected results of disclosed litigation and the projected timing of the courtas decision. Such statements entail a number of risks and uncertainties, including but not limited to: the inherent uncertainty of the outcome of any litigation, particularly patent litigation, the fact that the court could delay or accelerate the timing of its decision or require additional testimony, arguments or other steps prior to rendering its decision, and the companyas ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others. Reference is made to the discussion of these and other risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors" and elsewhere in such reports. Any forward-looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward-looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.

AzaSite and DuraSite are registered trademarks of InSite Vision Incorporated.

BESIVANCE is a registered trademark of Bausch & Lomb Incorporated.